Zacks Investment Research upgraded shares of aTyr Pharma (NASDAQ:LIFE) from a hold rating to a buy rating in a research report report published on Friday. The firm currently has $3.25 price target on the biotechnology company’s stock.
According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “
A number of other research analysts have also commented on LIFE. JPMorgan Chase & Co. lowered aTyr Pharma from a neutral rating to an underweight rating in a research report on Wednesday, February 14th. ValuEngine lowered aTyr Pharma from a sell rating to a strong sell rating in a research report on Friday, December 1st. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of $4.75.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its position in aTyr Pharma by 44.1% during the 3rd quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock valued at $423,000 after purchasing an additional 25,676 shares during the last quarter. Deutsche Bank AG bought a new position in shares of aTyr Pharma in the 4th quarter worth approximately $199,000. Victory Capital Management Inc. bought a new position in shares of aTyr Pharma in the 3rd quarter worth approximately $455,000. Renaissance Technologies LLC raised its position in shares of aTyr Pharma by 143.2% in the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock worth $978,000 after acquiring an additional 164,500 shares in the last quarter. Finally, Artal Group S.A. raised its position in shares of aTyr Pharma by 100.0% in the 4th quarter. Artal Group S.A. now owns 500,000 shares of the biotechnology company’s stock worth $1,750,000 after acquiring an additional 250,000 shares in the last quarter. 58.65% of the stock is owned by institutional investors and hedge funds.
About aTyr Pharma
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.